Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 29:9:943604.
doi: 10.3389/fsurg.2022.943604. eCollection 2022.

Role of metastasectomy in the management of renal cell carcinoma

Mark Mikhail  1 , Kevin J Chua  1 , Labeeqa Khizir  1 , Alexandra Tabakin  1 , Eric A Singer  1
Affiliations
Review

Role of metastasectomy in the management of renal cell carcinoma

Mark Mikhail et al. Front Surg. .

Abstract

Treatment of metastatic renal cell carcinoma (mRCC) has evolved with the development of a variety of systemic agents; however, these therapies alone rarely lead to a complete response. Complete consolidative surgery with surgical metastasectomy has been associated with improved survival outcomes in well-selected patients in previous reports. No randomized control trial exists to determine the effectiveness of metastasectomy. Therefore, reviewing observational studies is important to best determine which patients are most appropriate for metastasectomy for mRCC and if such treatment continues to be effective with the development of new systemic therapies such as immunotherapy. In this narrative review, we discuss the indications for metastasectomies, outcomes, factors associated with improved survival, and special considerations such as location of metastasis, number of metastases, synchronous metastases, and use of systemic therapy. Additionally, alternative treatment options and trials involving metastasectomy will be reviewed.

Keywords: Metastatic kidney cancer; metastasectomy; metastatic renal cell carcinoma; renal cancer; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Mark Mikhail – None Kevin Chua – None Labeeqa Khizir – None Alexandra Tabakin – None Eric A. Singer – Astellas/Medivation - research support (clinical trial) Merck - advisory board Johnson & Johnson - advisory board Vyriad - advisory board Aura Biosciences - data safety monitoring board member.

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. (2022) 72(1):7–33. 10.3322/caac.21708 - DOI - PubMed
    1. Doppalapudi SK, Leopold ZR, Thaper A, Kaldany A, Chua K, Patel HV, et al. Clearing up clear cell: clarifying the immuno-oncology treatment landscape for metastatic clear cell RCC. Cancers (Basel). (2021) 13(16):4140. 10.3390/cancers13164140 - DOI - PMC - PubMed
    1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. (2008) 372(9637):449–56. 10.1016/s0140-6736(08)61039-9 - DOI - PubMed
    1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. (2010) 116(18):4256–65. 10.1002/cncr.25219 - DOI - PubMed
    1. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. May. (2007) 356(22):2271–81. 10.1056/NEJMoa066838 - DOI - PubMed

LinkOut - more resources